Parkinson's Disease by Major Markets - Size, Trends and Drug Forecast including Epidemiology, Disease Management, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Pipeline Analysis to 2029

1.1 Parkinson’s market expected to grow significantly, driven by new launches
1.2 Significant opportunities and risks for disease-modifying therapies entering the PD market
1.3 Diverse pipeline agents will partially address key unmet needs
1.4 The advancement of levodopa delivery systems will shape the PD market
1.5 What do physicians think?

2.1 Catalyst
2.2 Related reports
2.3 Upcoming reports

3.1 Etiology and pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Mechanisms of cell death
3.2 Classification or staging systems

4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 Forecast methodology
4.4.1 Sources
4.4.2 Forecast assumptions and methods
4.5 Epidemiological forecast for PD (2019-29)
4.5.1 Diagnosed prevalent cases of PD
4.5.2 Sex-specific diagnosed prevalent cases of PD
4.5.3 Age-specific diagnosed prevalent cases of PD
4.5.4 Diagnosed prevalent cases of PD by Hoehn and Yahr clinical staging
4.5.5 Diagnosed prevalent cases of PD by type
4.6 Discussion
4.6.1 Epidemiological forecast insight
4.6.2 COVID-19 impact
4.6.3 Limitations of the analysis
4.6.4 Strengths of the analysis

5.1 Diagnosis and treatment overview
5.2 Key opinion leader insights on disease management

6.1 Overview

7.1 Overview
7.2 Effective treatment of motor complications - dyskinesia, off episodes, gait, and balance problems
7.3 New therapies for non-motor complications - psychosis and dementia
7.4 Neuroprotective or disease-modifying agents
7.5 Improved drug formulations

8.1 Overview
8.1.1 Development of novel targets - mAbs targeting a-synuclein and gene therapies
8.1.2 Innovative drug delivery systems
8.1.3 Secondary indications and drug repurposing
8.1.4 Clinical trial design
8.1.5 Reliable biomarkers of disease progression
8.1.6 Genetic studies required to learn about genetic subtypes of PD

9.1 Overview
9.2 Promising drugs in clinical development

10.1 Overview
10.2 Competitive assessment
10.2.1 Levodopa therapy
10.2.2 Dopamine agonists
10.2.3 Products targeting non-motor symptoms
10.2.4 Non-levodopa therapies
10.2.5 Therapies for levodopa-induced dyskinesia

11.1 Overview
11.2 Deal-making trends

12.1 Global markets
12.1.1 Forecast
12.1.2 Drivers and barriers - global issues
12.2 US
12.2.1 Forecast
12.2.2 Key events
12.2.3 Drivers and barriers
12.3 5EU
12.3.1 Forecast
12.3.2 Key events
12.3.3 Drivers and barriers
12.4 Japan
12.4.1 Forecast
12.4.2 Key events
12.4.3 Drivers and barriers

13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
13.3.1 Forecasting methodology
13.4 Primary research - key opinion leaders interviewed for this report
13.4.1 Key opinion leaders
13.5 Primary research - prescriber survey
13.6 About the authors
13.6.1 Analyst
13.6.2 Therapy Area Director
13.6.3 Epidemiologist
13.6.4 Managing Epidemiologist
13.6.5 Vice President of Disease Analysis and Intelligence
13.6.6 Global Head and EVP of Healthcare Operations and Strategy

• Contact the Publisher

Figure 1: Global sales forecast by country for PD in 2019 and 2029
Figure 2: Analysis of the Company Portfolio Gap in PD During the Forecast Period
Figure 3: 7MM, diagnosed prevalence (%) of PD, both sexes, ages =18 years, 2019
Figure 4: 7MM, sources used and not used to forecast the diagnosed prevalent cases of PD
Figure 5: 7MM, sources used to forecast the diagnosed prevalent cases of PD segmented by HY clinical staging
Figure 6: 7MM, diagnosed prevalent cases of PD, both sexes, N, ages =18 years, 2019
Figure 7: 7MM, diagnosed prevalent cases of PD by sex, N, ages =18 years, 2019
Figure 8: 7MM, diagnosed prevalent cases of PD by age, N, both sexes, 2019
Figure 9: 7MM, diagnosed prevalent cases of PD by HY clinical staging, N, both sexes, ages =18 years, 2019
Figure 10: 7MM, diagnosed prevalent cases of PD by type, N, both sexes, ages =18 years, 2019
Figure 11: Treatment algorithm for PD patients
Figure 12: Unmet needs and opportunities in PD
Figure 13: Pharmacokinetics of levodopa
Figure 14: Overview of the development pipeline in PD
Figure 15: Key late-stage trials for the promising pipeline agents that the publisher expects to be licensed for PD in the 7MM during the forecast period
Figure 16: Competitive assessment of the pipeline levodopa therapies benchmarked against the SOC, Sinemet
Figure 17: Competitive assessment of the pipeline dopamine agonist drugs benchmarked against the SOC, Requip XL
Figure 18: Competitive assessment of blarcamesine benchmarked against the SOC, Nuplazid
Figure 19: Competitive assessment of the pipeline non-levodopa drugs benchmarked against the SOC, Azilect
Figure 20: Competitive assessment of the pipeline levodopa-induced dyskinesia drugs benchmarked against the SOC, Gocovri (amantadine ER)
Figure 21: Analysis of the company portfolio gap in PD during the forecast period (2019-29)
Figure 22: Global (7MM) sales forecast by country for PD in 2019 and 2029
Figure 23: Sales forecast by class for PD in the US in 2019 and 2029
Figure 24: Sales forecast by class for PD in the 5EU in 2019 and 2029
Figure 25: Sales forecast by class for PD in Japan in 2019 and 2029